<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03829514</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00079289</org_study_id>
    <nct_id>NCT03829514</nct_id>
  </id_info>
  <brief_title>Fenofibrate in Type 2 Diabetes</brief_title>
  <official_title>Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once
      in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in
      diabetic retinopathy offers an important translational research opportunity. The
      investigator's global proteomic study will provide new clues as to how fenofibrate protects
      vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in levels of individual plasma proteins, measured as ion current, in proteomic analysis via liquid chromatography-mass spectrometry</measure>
    <time_frame>Baseline through six weeks</time_frame>
    <description>Plasma proteomics enables the study of complex disease processes. Combined with bioinformatics, proteomics is a powerful and unbiased approach that can identify pathways for the multi-organ benefits of fenofibrate, defining new target</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm. Participants will take study medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides &gt;150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.</description>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>Trilipix</other_name>
    <other_name>Triglide</other_name>
    <other_name>Antara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes of at least one year's duration; stable glycemic control (no more than
             1.0% change in HbA1c in the previous six months, but no limit on HbA1c)

          -  Triglycerides &gt;150 mg/dL (in the previous six months)

        Exclusion Criteria:

          -  Previous use of Fenofibrate or other fibrates

          -  Pregnancy

          -  Active malignancy

          -  Recent cardiac event or congestive heart failure

          -  Active liver disease

          -  Significant renal impairment (serum creatinine &gt; 2mg/dl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Misti J Leyva, PhD</last_name>
    <phone>8437921933</phone>
    <email>leyva@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misti J Leyva, PhD</last_name>
      <phone>843-792-1933</phone>
      <email>leyva@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Timothy Lyons</investigator_full_name>
    <investigator_title>Professor and Chief, Division of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

